Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2021 · 10-Q
Revenue$148.46M$148.46M−4.3% vs Q3 2020 Net Income$21.56M$21.56M−46.1% vs Q3 2020 EPS Diluted$0.40$0.40−45.9% vs Q3 2020 Operating Income$32,604,000−41.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin22.0%−14.2 pt vs Q3 2020
Net margin14.5%−11.3 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 5, 2021 · 36 d after period end